December 18, 2024
Ultimovacs ASA – Mandatory notification of trade
Reference is made to the stock exchange announcement by Ultimovacs ASA (the “Company”) on 17 December 2024 regarding the agreement…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
December 18, 2024
ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR…
December 17, 2024
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
Tuesday, December 17, 2024 at 8:00 am ESTREDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”)…
December 17, 2024
Reviva Announces Proposed Public Offering
CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…
December 17, 2024
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…
December 17, 2024
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in…
December 16, 2024
ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue Therapeutics
Italian clinical-stage oncology company BetaGlue Therapeutics, developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose, announced Monday that the ENEA-Tech and Biomedical Foundation (“ENEA-Tech”) has invested €6m bringing the total raised in the current funding round to €24m.
December 16, 2024
Novo Nordisk to invest 8.5 billion Danish kroner (€1.14B) in new production facility in Denmark.
Novo Nordisk announced Monday it plans to invest 8.5 billion Danish kroner (€1.14B) to establish a completely new production facility in Odense, Denmark.
December 16, 2024
Swiss Basilea partners up with Innoviva to sell anti MRSA antibiotic Zevtera in the US
Basilea Pharmaceutica, a Swiss bacterial and fungal infections biopharmaceutical specialist, has entered into an exclusive distribution and license agreement with…
December 16, 2024
Pharming announces public cash offer to the shareholders of Abliva AB
Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal…